{"product_id":"2940148308362","title":"Good Clinical Practice eRegs \u0026 Guides - For Your Reference Book 6","description":"ICH - Safety Guidelines S1A – S9 \u003cbr\u003e\u003cbr\u003eS1A Guideline on the Need for Carcinogenicity Studies \u003cbr\u003e\u003cbr\u003eS1B Testing for Carcinogenicity of Pharmaceuticals \u003cbr\u003e\u003cbr\u003eS1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals \u003cbr\u003e\u003cbr\u003eS2(R1) Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use \u003cbr\u003e\u003cbr\u003eS3A Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies \u003cbr\u003ePharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies \u003cbr\u003e\u003cbr\u003eS4 Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing) \u003cbr\u003e\u003cbr\u003eS5(R2) Detection of Toxicity to Reproduction for Medicinal Products \u0026amp; Toxicity to Male Fertility \u003cbr\u003e\u003cbr\u003eS6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals \u003cbr\u003e\u003cbr\u003eS7A Safety Pharmacology Studies For Human Pharmaceuticals \u003cbr\u003e\u003cbr\u003eS7B The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) By Human Pharmaceuticals \u003cbr\u003e\u003cbr\u003eS8 Immunotoxicity Studies for Human Pharmaceuticals \u003cbr\u003e\u003cbr\u003eS9 Nonclinical Evaluation for Anticancer Pharmaceuticals","brand":"Biopharma Advantage Consulting L.L.C.","offers":[{"title":"Default Title","offer_id":47075369418992,"sku":"2940148308362","price":9.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0737\/7593\/9824\/files\/2940148308362_p0.jpg?v=1763700891","url":"https:\/\/shop-qa.barnesandnoble.com\/products\/2940148308362","provider":"Barnes \u0026 Noble (DEV)","version":"1.0","type":"link"}